GMED insider trades: 25,000 options exercised and 25,000 shares sold

Rhea-AI Filing Summary

Globus Medical Inc. (GMED) director reported an insider transaction involving company Class A common stock. On 11/12/2025, the reporting person exercised 25,000 stock options at an exercise price of $25.52 per share and on the same date sold 25,000 shares of Class A common stock at a weighted average price of $86.0002 per share. After these transactions, the director directly beneficially owns 516,275 shares of Class A common stock and indirectly beneficially owns 165,967 shares held in a family trust. The reported options were granted on January 25, 2016 and are fully vested.

Insider Trade Summary

Net Seller: 25,000 shares ($2,150,005)

Net Sell 4 txns

Insider Davidar David D

Role Director

Sold 25,000 shs ($2.15M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy Class A Common Stock)	25,000	$0.00	--
Exercise	Class A Common Stock	25,000	$25.52	$638K
Sale	Class A Common Stock	25,000	$86.0002	$2.15M
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 0 shares (Direct); Class A Common Stock — 541,275 shares (Direct); Class A Common Stock — 165,967 shares (Indirect, By Davidar Family Irrevocable Trust U/A 8/6/09)

Footnotes (1)

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at a price range of $86.00 - $86.01, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the range set forth in footnote (1) of this Form 4. These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is trustee of the trust. These options were granted on January 25, 2016 and are fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davidar David D

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/12/2025		M		25,000	A	$25.52	541,275	D
Class A Common Stock	11/12/2025		S		25,000	D	$86.0002(1)	516,275	D
Class A Common Stock								165,967	I	By Davidar Family Irrevocable Trust U/A 8/6/09(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$25.52	11/12/2025		M			25,000	(3)	01/25/2026	Class A Common Stock	25,000	$0	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at a price range of $86.00 - $86.01, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the range set forth in footnote (1) of this Form 4.

2. These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is trustee of the trust.

3. These options were granted on January 25, 2016 and are fully vested.

	/s/ Kelly G. Huller, Attorney-in-Fact	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Globus Medical (GMED) report in this Form 4?

The filing reports that a director of Globus Medical exercised 25,000 stock options for Class A common stock and sold 25,000 shares of Class A common stock on 11/12/2025.

At what prices did the Globus Medical (GMED) director exercise options and sell shares?

The director exercised stock options at an exercise price of $25.52 per share and sold 25,000 shares at a weighted average price of $86.0002 per share, with individual trades between $86.00 and $86.01.

How many Globus Medical (GMED) shares does the insider own after the reported transactions?

Following the transactions, the director directly beneficially owns 516,275 shares of Globus Medical Class A common stock and indirectly beneficially owns 165,967 shares held in a family trust.

What is the nature of the indirect ownership reported for Globus Medical (GMED)?

The filing states that 165,967 shares are held in a trust for the benefit of the reporting person's spouse and children, with the spouse serving as trustee.

What details are provided about the Globus Medical (GMED) stock options involved?

The derivative table shows a stock option to buy Class A common stock at an exercise price of $25.52, covering 25,000 shares. These options were granted on January 25, 2016 and are reported as fully vested.

How many derivative securities does the Globus Medical (GMED) insider hold after the transaction?

After exercising the reported stock options covering 25,000 shares, the number of those derivative securities beneficially owned is reported as 0.